Bristol Myers Yervoy shows no incremental benefit on Merck Keytruda alone in lung cancer

Based on the recommendation from the independent Data Monitoring Committee that the study is unlikely to succeed, Merck (NYSE:MRK) is terminating the Phase 3 KEYNOTE-598 study evaluating the combination of Keytruda (pembrolizumab) and Bristol Myers Squibb's (NYSE:BMY) Yervoy (ipilimumab) compared to Keytruda alone for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (tumor proportion score [TPS] ≥50%) with no EGFR or ALK genomic tumor aberrations.

• The addition of Yervoy showed no incremental benefit in overall survival (OS) or progression-free survival (PFS), the primary endpoints, compared to Keytruda alone.
• On the safety front, the combo therapy was associated with higher rates of serious, life-threatening and fatal adverse events compared to Keytruda monotherapy.
• Results will be submitted for presentation at a future medical conference.

https://seekingalpha.com/news/3634036-bristol-myers-yervoy-shows-no-incremental-benefit-over-mercks-keytruda-alone-in-lung-cancer